tiprankstipranks
China Tian Yuan Healthcare Group Limited (HK:0557)
:0557
Hong Kong Market
Want to see HK:0557 full AI Analyst Report?

China Tian Yuan Healthcare Group Limited (0557) AI Stock Analysis

1 Followers

Top Page

HK:0557

China Tian Yuan Healthcare Group Limited

(0557)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 5.2)
Rating:47Neutral
Price Target:
HK$0.59
▼(-15.57% Downside)
Action:Reiterated
Date:06/27/26
The score is primarily held back by weak financial performance, especially steep revenue declines and sustained operating/net losses despite decent gross margins. Technicals are mixed with some intermediate support but weakness versus key shorter/longer moving averages and a potentially stretched stochastic reading. Valuation is penalized due to negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
High gross margins
Sustained gross margins above ~50% indicate the core distribution business retains healthy unit economics and pricing power. This margin buffer is a durable strength: if revenue stabilizes, it can absorb SG&A and support a path to operating breakeven without requiring radical price changes.
Negative Factors
Sharp revenue contraction
A multi-year top-line decline (≈27% in 2025) erodes scale, reduces operating leverage, and weakens market position. Persistent revenue loss makes fixed-cost absorption harder and limits the ability to invest in distribution or customer retention, posing a durable headwind unless growth reverses.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins above ~50% indicate the core distribution business retains healthy unit economics and pricing power. This margin buffer is a durable strength: if revenue stabilizes, it can absorb SG&A and support a path to operating breakeven without requiring radical price changes.
Read all positive factors

China Tian Yuan Healthcare Group Limited (0557) vs. iShares MSCI Hong Kong ETF (EWH)

China Tian Yuan Healthcare Group Limited Business Overview & Revenue Model

Company Description
China Tian Yuan Healthcare Group Limited, an investment holding company, provides healthcare related services in Hong Kong, the People's Republic of China, and Korea. It operates through Investment Holding, Healthcare, Money Lending and Related Bu...
How the Company Makes Money
null...

China Tian Yuan Healthcare Group Limited Financial Statement Overview

Summary
Income statement quality is weak (Income Statement Score 24) with sharp multi-year revenue contraction and persistent operating/net losses despite solid gross margins. The balance sheet is moderately positioned (Score 58) with manageable leverage but declining equity and negative ROE. Cash flow is somewhat supportive (Score 55) with positive operating/free cash flow in 2023–2025, though volatility and ongoing losses limit confidence.
Income Statement
24
Negative
Balance Sheet
58
Neutral
Cash Flow
55
Neutral
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue19.18M26.84M45.23M54.22M94.59M
Gross Profit9.59M14.91M24.98M34.83M71.31M
EBITDA-3.51M-27.22M-15.79M-13.08M-2.89M
Net Income-34.01M-34.24M-15.48M-29.04M-16.85M
Balance Sheet
Total Assets224.98M260.93M302.95M333.55M376.40M
Cash, Cash Equivalents and Short-Term Investments29.51M27.05M26.73M31.60M77.89M
Total Debt38.72M45.97M45.91M51.13M59.66M
Total Liabilities88.36M84.98M87.77M91.52M92.35M
Stockholders Equity161.22M194.68M230.26M224.30M256.25M
Cash Flow
Free Cash Flow9.12M10.67M4.51M-31.71M14.86M
Operating Cash Flow9.41M10.69M5.10M-30.36M16.32M
Investing Cash Flow-292.00K-3.00K364.00K-1.23M-1.42M
Financing Cash Flow-5.05M-10.85M-8.77M-12.49M-7.22M

China Tian Yuan Healthcare Group Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.70
Price Trends
50DMA
0.54
Positive
100DMA
0.57
Positive
200DMA
0.68
Negative
Market Momentum
MACD
0.02
Positive
RSI
49.86
Neutral
STOCH
73.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0557, the sentiment is Negative. The current price of 0.7 is above the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.54, and above the 200-day MA of 0.68, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.86 is Neutral, neither overbought nor oversold. The STOCH value of 73.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0557.

China Tian Yuan Healthcare Group Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
HK$768.85M2.965.42%4.67%-4.47%0.64%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
66
Neutral
HK$1.63B29.300.57%3.37%0.33%-77.16%
66
Neutral
HK$590.51M73.330.19%6.25%
66
Neutral
HK$1.84B16.182.64%1.95%-2.47%38.92%
47
Neutral
HK$239.39M-3.82-33.69%-28.56%0.58%
41
Neutral
HK$341.54M-0.27-29.62%51.08%55.72%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0557
China Tian Yuan Healthcare Group Limited
0.60
-0.18
-23.08%
HK:0184
Keck Seng Investments (Hong Kong)
2.26
0.12
5.71%
HK:1270
Langham Hospitality Investments
0.46
-0.10
-17.27%
HK:0201
Magnificent Hotel Investments Limited
0.07
>-0.01
-5.71%
HK:1221
Sino Hotels (Holdings) Ltd.
1.54
0.17
12.00%
HK:0078
Regal Hotels International Holdings Limited
0.38
-0.27
-41.54%

China Tian Yuan Healthcare Group Limited Corporate Events

China Tian Yuan Healthcare to Sell Majority Stake in Subsidiary for RMB23 Million
Jun 9, 2026
China Tian Yuan Healthcare Group Limited has agreed to dispose of a 60.8077% equity stake in a subsidiary, referred to as the Target Company, held through its indirect wholly owned unit Hengqin Hanyuemei. The stake, representing registered capital...
China Tian Yuan Healthcare Moves to Re-elect Long-Serving Independent Director
May 29, 2026
China Tian Yuan Healthcare Group Limited has issued a supplemental announcement to its May 27, 2026 circular, clarifying arrangements for the re-election of long-serving independent non-executive director (INED) Mr. Yuen Kwok Kuen at its upcoming ...
China Tian Yuan Healthcare Calls 2026 AGM, Seeks Fresh Share Issue Mandate
May 27, 2026
China Tian Yuan Healthcare Group Limited has called its thirty-seventh annual general meeting for 29 June 2026 in Hong Kong, where shareholders will review the audited consolidated financial statements for the year ended 31 December 2025 and the r...
China Tian Yuan Healthcare Unit Signs 2026 Connected Services Deal With Parent
Apr 20, 2026
China Tian Yuan Healthcare Group’s indirect non-wholly owned subsidiary Deshang Clinic has entered into a 2026 Service Framework Agreement with ultimate holding company Ningxia Tianyuan, under which it will provide occupational health examin...
China Tian Yuan Healthcare Posts Another Annual Loss on Lower Revenue and Goodwill Impairment
Mar 30, 2026
China Tian Yuan Healthcare Group Limited, a Hong Kong-listed healthcare group incorporated in the Cayman Islands, reported audited consolidated results for the year ended 31 December 2025. The company’s activities span healthcare operations ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2026